Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Beigene, Hangzhou Chance, Humanigen, Immutep, Innovent, Janssen-Cilag International, Moderna, Opthea, Recipharm, Replicel Life Sciences, Sciclone, Y-Mabs, Zydus Cadila.